2013
Gilead's hepatitis C drug Sovaldi was approved by the FDA and came to market in December 2013.
“The medication was approved by the FDA and came to market in December 2013.”
Topic
6 facts from 4 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
2013
Gilead's hepatitis C drug Sovaldi was approved by the FDA and came to market in December 2013.
“The medication was approved by the FDA and came to market in December 2013.”
Undated
insitro's liver disease work came out of its partnership with Gilead Sciences on NASH, non-alcoholic steatohepatitis.
“It came out of the partnership that we have with Gilead on NASH, non-alcoholic steatohepatitis.”
Undated
Gilead's originally proposed price for Sovaldi was $84,000, which Andrew Lowe calls a bargain from an economist's point of view.
“Gilead's original proposed market price was $84 ,000. And from an economist's point of view, that was a bargain.”
Undated
Louisiana agreed to pay Gilead a fixed monthly amount per member, and Gilead agreed to treat all people in the state who needed the hepatitis C drug.
“the state of Louisiana developed an interesting approach. They agreed to pay Gilead a certain amount of money per member per month”
Undated
Gilead spent nearly $5 billion acquiring Forty Seven Inc. for its CD47 drug magrolimab, and the program was later scrapped.
“Gilead spent nearly $5 billion acquiring 47 Inc. to get their flagship CD47 drug, Migrolumab.”
Undated
Gilead Sciences, Insitro's first partner, decided to exit liver disease and focus on virology and oncology.
“they are exiting the liver space and focusing on virology and oncology”
Episodes